{
    "clinical_study": {
        "@rank": "129601", 
        "arm_group": [
            {
                "arm_group_label": "Dose 1 JTT-252 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fasted condition"
            }, 
            {
                "arm_group_label": "Dose 2 JTT-252 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fasted condition"
            }, 
            {
                "arm_group_label": "Dose 3 JTT-252 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fasted condition"
            }, 
            {
                "arm_group_label": "Dose 4 JTT-252 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fasted condition"
            }, 
            {
                "arm_group_label": "Dose 5 JTT-252 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fasted condition"
            }, 
            {
                "arm_group_label": "Dose 6 JTT-252 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fasted condition"
            }, 
            {
                "arm_group_label": "Dose 7 JTT-252 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fasted condition"
            }, 
            {
                "arm_group_label": "Dose 8 JTT-252", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fed condition"
            }, 
            {
                "arm_group_label": "Dose 9 JTT-252", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, single dose in fasted condition"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability, and PK of single oral\n      doses of JTT-252 and the effect of food on the PK of JTT-252 in healthy subjects, and to\n      evaluate the safety, tolerability, PK and PD of single oral doses of JTT-252 in type 2\n      diabetes mellitus subjects."
        }, 
        "brief_title": "Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Healthy Subject Cohorts:\n\n          -  Healthy male or female subjects\n\n          -  Age 18 to 50 Years (inclusive)\n\n          -  Body Mass Index (BMI) between 19.0 and 31.0 kg/m2 (inclusive)\n\n        Type 2 Diabetic Subject Cohorts:\n\n          -  Male or female Type 2 diabetic subjects who are currently being treated with a stable\n             dose of metformin\n\n          -  Age 18 to 65 Years (inclusive)\n\n          -  BMI between 25.0 and 40.0 kg/m2 (inclusive)\n\n          -  Have a glycosylated hemoglobin (HbA1c) of >7.0% to \u22649.5%\n\n          -  Have a fasting plasma glucose (FPG) <240 mg/dL\n\n        Exclusion Criteria:\n\n        Healthy Subject Cohorts:\n\n          -  Known clinically relevant history or presence of significant respiratory,\n             gastrointestinal, renal, hepatic, hematological, lymphatic, neurological,\n             cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, metabolic\n             and dermatological or connective tissue disease\n\n          -  Subjects with a systolic blood pressure >140 mmHg and/or diastolic blood pressure >90\n             mmHg\n\n        Type 2 Diabetic Subject Cohorts:\n\n          -  Subjects with a known medical history or presence of type 1 diabetes mellitus\n\n          -  Subjects with known medical history of acute metabolic diabetic complications\n\n          -  Subjects with uncontrolled hypertension (systolic blood pressure >150 mmHg and/or\n             diastolic blood pressure >95 mmHg"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "88", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02120976", 
            "org_study_id": "AT252-U-14-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Dose 1 JTT-252 or Placebo", 
                    "Dose 2 JTT-252 or Placebo", 
                    "Dose 3 JTT-252 or Placebo", 
                    "Dose 4 JTT-252 or Placebo", 
                    "Dose 5 JTT-252 or Placebo", 
                    "Dose 6 JTT-252 or Placebo", 
                    "Dose 7 JTT-252 or Placebo"
                ], 
                "description": "Subjects will receive JTT-252 or Placebo", 
                "intervention_name": "JTT-252 or Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Dose 8 JTT-252", 
                    "Dose 9 JTT-252"
                ], 
                "description": "Subjects will receive JTT-252", 
                "intervention_name": "JTT-252", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Safety", 
            "Tolerability", 
            "Pharmacokinetics", 
            "Food-effect", 
            "Diabetes"
        ], 
        "lastchanged_date": "April 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "9", 
        "official_title": "A Phase 1, Randomized, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Single Oral Doses of JTT-252 in Healthy Subjects (Part I); in Conjunction With an Open-label Study to Evaluate the Effect of Food on the PK of JTT-252 in Healthy Subjects (Part II); and an Open-label Study to Evaluate the Safety, Tolerability, PK and Pharmacodynamics (PD) of Single Oral Doses of JTT-252 in Type 2 Diabetic Subjects (Part III)", 
        "overall_contact": {
            "email": "yamamotoh@akrospharma.com", 
            "last_name": "Hideyuki Yamamoto", 
            "phone": "609-919-6111"
        }, 
        "overall_official": {
            "affiliation": "Akros Pharma Inc.", 
            "last_name": "Hideyuki Yamamoto", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "22 days"
            }, 
            {
                "measure": "Vital signs and 12 lead ECGs", 
                "safety_issue": "Yes", 
                "time_frame": "22 days"
            }, 
            {
                "measure": "Cmax (maximum concentration)", 
                "safety_issue": "No", 
                "time_frame": "22 days"
            }, 
            {
                "measure": "t1/2 (elimination half-life)", 
                "safety_issue": "No", 
                "time_frame": "22 days"
            }, 
            {
                "measure": "AUC (area under the concentration-time curve)", 
                "safety_issue": "No", 
                "time_frame": "22 days"
            }, 
            {
                "measure": "fe(total) (fraction of systemically available drug excreted into the urine over entire collection interval)", 
                "safety_issue": "No", 
                "time_frame": "3 days"
            }, 
            {
                "measure": "Plasma glucose", 
                "safety_issue": "No", 
                "time_frame": "22 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02120976"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Akros Pharma Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Akros Pharma Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}